Select a Region North America

Expertise

Faruk Abdullah

President, Professional Services and Chief Business Officer

Expertise:

Consulting (Strategy Management & Regulatory)

Faruk is a life sciences professional with extensive experience addressing a broad range of strategic issues, including corporate development, portfolio planning, and launch excellence. Prior to joining EVERSANA MANAGEMENT CONSULTING he helped clients apply advanced analytic software technologies to draw unique insights from clinical and commercial data and focused on shaping and executing strategic initiatives for large- and mid-cap life sciences companies.

In addition to being a strategic advisor, Faruk has contributed to entrepreneurial efforts, developing products in both the therapeutic and medical device spaces. He has authored a number of articles that have helped companies consider novel approaches to developing and commercializing their products. He has shared unique perspectives on how companies can adapt their commercial models to an evolving healthcare ecosystem and offered insights on how organizations can rethink the development and integration of analytic capabilities to inform strategic decisions.

Faruk holds an MBA from Harvard Business School and a BS in electrical engineering from Northwestern University.

Articles by Faruk Abdullah

IDN Trends, Insights and Strategies Every Manufacturer Should Know

In this latest webinar, hear from three industry experts as the delve into the intricacies of integrated delivery networks (IDNs)  and how they are transforming the healthcare landscape. EVERSANA’s Faruk Abdullah and Krista Pinto, and Matthew Wilkins from G1 Therapeutics provide a comprehensive overview of the current trends and future direction of healthcare, particularly the […]

Optimizing Product Commercialization in Today’s IDN Environment

The healthcare landscape is undergoing a significant transformation with the rise of Integrated Delivery Networks (IDNs), now employing nearly 70% of U.S. physicians. As IDNs become more prevalent, they bring numerous advantages, such as enhanced physician collaboration across specialties, increased operational efficiencies and improved patient care outcomes. IDNs not only centralize their purchasing efforts but […]

M&A and BD&L Outlook and Perspectives on Commercial Due Diligence

In this webinar, industry leaders Faruk Abdullah, Jakub Pijewski, PhD, and Yao Zhang, PhD, delve into the dynamic world of M&A, BD&L, and Commercial Due Diligence (CDD) in the pharmaceutical and biotech sectors. Gain valuable insights into: Current perspectives on deal-making trends The heightened importance of CDD Best practices and risk mitigation techniques for optimizing CDD […]

Maximize In-Licensing Growth

In-licensing is a significant growth lever for a variety of reasons, including: Serving as a risk mitigation tool Reinforce a company’s therapeutic area footprint Serving as a growth catalyst channel to further diversify your pipeline and product portfolio. A Once-in-a-Lifetime Moment of Market Conditions The opportunity at hand for large pharma has been created by […]

Three Keys to Value for Unlocking the Promise of Cell Therapies

The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1  The revenue generation is being driven by technological advancements in manufacturing processes and developments in CAR T-cell therapy for solid tumors, and the approvals and […]

Overcome In-Licensing Barriers to Increase Throughput of Assets

In-licensing is an important growth channel for pharmaceutical companies as they continue to seek more catalysts for growth. In-licensing is used to expand or consolidate a company’s position in a therapy area but can oftentimes be limited by internal restraints. Common Barriers to In-Licensing: Capacity and Capability Constraints Many times, companies are limited in in-licensing […]

Reigniting Revenue for Established Brands

Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease in utilization and patient access due to the pandemic, making them vulnerable to negative financial impacts that are difficult […]

Reignite Established Brands — Actual Use Case

EVERSANA™ REIGNITE Commercialization serves as a catalyst for biopharma companies to address the management of their established brand portfolios. In a recent study, EVERSANA reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE Commercialization model to slow financial loss and make a positive impact on revenue. With a combined investment, these established […]

Podcast: Achieving Cell and Gene Therapy Commercial Excellence

There is no question about the incredible clinical impact cell and gene therapies (CGTs) can have on the lives of patients. However, this impact is the result of innovation that does not equate to a simple, straightforward commercialization process. The commercialization and management requirements of these treatments are just as complex as their innovative science. […]

webinar-insights
Driving Commercial Excellence for CAR-T

In this session from the 6th Annual CAR-TCR Summit, Faruk Abdullah, Head of U.S. Consulting, EVERSANA™ MANAGEMENT CONSULTING and Maria Kirsch, SVP & Head of Patient Services share insight on building the future commercialization model designed specifically for CAR-T, including: Key differences between CAR-T and traditional therapies Ideas, tactics and techniques needed to address CAR-T’s […]

Learning How to Play Dilution Dodgeball

The healthcare industry is reaching new heights in innovation, and as new drugs are founded, owners of biotech companies must decide whether or not they want to independently bring their product to market.  Developing and successfully commercializing a biopharma product is no small undertaking. The multi-year journey is fraught with clinical, financial and operational uncertainties that many companies fail […]

Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth

As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market […]

The Crush: How Covid-19 Is Impacting Mature Brand Revenue & Long-Term Value

The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their clinical outcomes. The clinical consequences of this will lead to compromised patient outcomes and further healthcare cost increases. This […]

Moving Forward in Pharma: Reigniting Revenue for Mature Brands

The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future indications emerging for mature brands. Mature brands, or non-promoted in-line brands, are the bread-and-butter products for pharma companies in […]

The Chronic Microcap Trap: How Launch Is The Escape for True Growth

Pre-commercial pharma companies face a common choice: commercialize products independently or collaborate with another pharmaceutical company as a commercialization partner. As the C-suite leaders in these organizations wrestle with the pros and cons of this choice, one factor they must consider is the impact their decision will have on their current and future market valuation. […]

Interested in scheduling a meeting or speaking event?

문의